Daily Respiratory Research Analysis
Analyzed 149 papers and selected 3 impactful papers.
Summary
Three impactful respiratory papers stood out today: a COPDGene analysis showed that lung volume-based pre-COPD phenotypes have distinct plasma proteomic signatures and higher progression risk; a Science Advances study revealed Vγ1 γδ T cells drive airway macrophages toward profibrotic states in lung cancer; and an intranasal nanovaccine induced durable systemic and mucosal immunity that curtailed SARS-CoV-2 replication in upper and lower airways.
Research Themes
- Pre-COPD stratification by lung volumes and plasma proteomics
- Tumor–immune crosstalk shaping profibrotic macrophage states in lung cancer
- Intranasal nanovaccines achieving durable mucosal and systemic anti-viral immunity
Selected Articles
1. Vγ1 γδ T cells steer airway macrophages toward a profibrotic response in an autochthonous lung cancer mouse model.
In an autochthonous lung cancer mouse model, tumors expand specific γδ T cell subsets, with Vγ1 γδ T cells directing airway macrophages toward a profibrotic state. This reveals a γδ T cell–macrophage axis that can promote tumor-associated fibrosis and reshape the tumor microenvironment.
Impact: This mechanistic work uncovers a previously unappreciated γδ T cell–driven programming of airway macrophages toward fibrosis in lung cancer, suggesting new immuno-fibrotic targets.
Clinical Implications: Targeting Vγ1 γδ T cell–macrophage crosstalk or downstream profibrotic programs may mitigate tumor-associated fibrosis and improve response to therapy in lung cancer.
Key Findings
- Tumors in a genetically engineered mouse model expand γδ T cell subsets, including Vγ1 cells.
- Vγ1 γδ T cells skew airway macrophages toward a profibrotic phenotype within the tumor microenvironment.
- Findings define a γδ T cell–macrophage axis linking tumor growth to fibrotic remodeling.
Methodological Strengths
- Use of an autochthonous genetically engineered lung cancer model enhances physiologic relevance.
- In vivo immune cell interaction mapping provides mechanistic insight into macrophage programming.
Limitations
- Preclinical murine findings require validation in human tissues and across tumor subtypes.
- Therapeutic modulation of the identified axis was not tested in interventional studies.
Future Directions: Validate γδ T cell–macrophage pathways in human lung cancer, define molecular mediators of profibrotic programming, and test targeted interventions to disrupt this axis.
γδ T cells are important for host defense at the respiratory mucosa, acting directly or through interactions with other cells. However, how γδ T cells influence other immune cells in the lung remains unclear. Using a genetically engineered mouse model of lung cancer, we show that tumors drive expansion of both CD27
2. Plasma proteomic profiles of lung volume-based phenotypes in Tobacco-Exposed Individuals Without Spirometric COPD.
In 1,959 TEPS participants, lung volume-based pre-COPD phenotypes exhibited distinct plasma proteomic signatures and different risks of COPD progression. Over 5.3 years, pre-COPD TEPS had higher incident spirometric COPD (adjOR 2.51), with FRC/TLChigh showing greater progression to GOLD ≥2 and PRISm; proteomic differences implicated immune and trafficking pathways.
Impact: This study links early physiological phenotypes to circulating proteomic biology and future COPD risk, enabling biomarker-driven pre-COPD stratification.
Clinical Implications: Plasma proteomic markers combined with lung volumes could identify high-risk individuals for surveillance, preventive interventions, or trial enrichment before spirometric COPD develops.
Key Findings
- Pre-COPD TEPS progressed to spirometric COPD more often than low-risk TEPS over 5.3±1.1 years (17% vs 8%; adjOR 2.51).
- FRC/TLChigh phenotype showed higher progression to GOLD ≥2 (adjOR 2.90) and PRISm (adjOR 3.29).
- Distinct proteomic signatures: 165 up and 145 down proteins in TLChigh vs low-risk; only 22 proteins differed in FRC/TLChigh vs low-risk; sRAGE, IGFBP2, and novel candidates (e.g., ZG16) featured prominently.
- Pathways implicated included immune signaling, cellular trafficking, and apoptosis relevant to COPD pathogenesis.
Methodological Strengths
- Large well-characterized cohort with CT-derived lung volumes and high-throughput SomaScan proteomics.
- Multivariable adjustment, machine learning, and longitudinal validation of prognostic relevance.
Limitations
- Observational design limits causal inference; external validation across cohorts and platforms is needed.
- Aptamer-based proteomics may require cross-platform standardization for clinical deployment.
Future Directions: Validate proteomic panels in independent cohorts, integrate with imaging/omics for risk models, and test biomarker-guided prevention trials in pre-COPD.
BACKGROUND: Among individuals with a history of smoking but preserved spirometry (tobacco exposed with preserved spirometry, or TEPS), lung volume-based stratification identifies two phenotypes at increased risk for COPD (pre-COPD): those with a relatively elevated total lung capacity ([TLC]high) and those with a relatively elevated functional residual capacity-to-TLC ratio ([FRC/TLC]high). These subgroups exhibit distinct respiratory symptoms, radiographic abnormalities, and clinical trajectories. OBJECTIVE: To determine whether these lung volume-based pre-COPD phenotypes have distinct biological features reflected in their circulating proteome. METHODS: We analyzed peripheral blood proteomic profiles (SomaScan v4.0; 4,979 aptamers) and computerized tomography scan-derived supine lung volumes from 1,959 TEPS participants at the 5-year follow-up visit (Visit 2) of the COPDGene cohort. Participants with [TLC]high and [FRC/TLC]high were compared with a low-COPD-risk reference group (without high TLC or high FRC/TLC). Analyses included covariate-adjusted regression, machine learning, and pathway enrichment modeling, adjusting for age, sex, height, weight, smoking status and burden, leukocyte and platelet counts, forced expiratory volume in 1 second (FEV1 as percent predicted), and study site (random effect). RESULTS: Using Visit 2 data and Visit 3 (10-year) follow-up outcomes, we confirmed the reproducibility and prognostic validity of the lung volume-based phenotypes in 1,232 participants with longitudinal data. Over 5.3 ± 1.1 years, spirometric COPD developed in 17% (133/761) of pre-COPD TEPS versus 8% (37/471) of low-risk TEPS (adjOR = 2.51 [1.69-3.75]; P < .001). Among pre-COPD subgroups, [FRC/TLC]high TEPS showed greater progression to GOLD ≥ 2 (adjOR = 2.90 [1.62-5.18]; P < .001) and PRISm (adjOR = 3.29 [1.41-7.69]; P = .005). At baseline (n = 1,959), plasma proteomic analysis identified 165 upregulated and 145 downregulated proteins in [TLC]high TEPS compared with low-COPD-risk TEPS, whereas only 22 proteins were differentially expressed in [FRC/TLC]high TEPS versus low-risk group. Comparison of the two pre-COPD phenotypes 269 differentially expressed proteins (116 proteins upregulated and 153 downregulated in [FRC/TLC]high versus [TLC]high), including previously described COPD-related mediators (e.g., sRAGE, IGFBP2) and novel candidates (e.g., ZG16). Pathway analysis highlighted immune signaling, cellular trafficking, and apoptotic pathways relevant to COPD pathogenesis. CONCLUSIONS: Lung volume-based stratification in TEPS identifies biologically distinct subgroups with differing plasma proteomic signature and COPD risk, underscoring the heterogeneity of early disease and revealing potential circulating biomarkers of pre-COPD states.
3. An innovative nasal nanovaccine against SARS-CoV-2 induces systemic and upper airway immunity controlling viral replication.
A mucoadhesive silica nanoparticle intranasal platform delivering SARS-CoV-2 RBD and T-cell epitopes elicited durable neutralizing and cellular responses with airway IgA for at least one year, markedly reducing viral loads in both upper and lower respiratory tracts. Dual nanoscale strategies enabled mucus adherence and penetration for robust mucosal immunity.
Impact: Demonstrates a translatable intranasal nanovaccine achieving durable systemic and mucosal immunity, addressing the key gap of upper-airway protection to curb infection and transmission.
Clinical Implications: If validated in humans, this platform could complement injectable vaccines by preventing infection/transmission via upper-airway IgA, informing booster design and pandemic preparedness.
Key Findings
- Intranasal delivery via mucoadhesive silica nanoparticles (SiNP+MaP) induced durable neutralizing antibodies and robust T-cell responses for at least 1 year.
- Significant induction of mucosal IgA in oral and nasal cavities accompanied reductions in viral loads in both upper and lower respiratory tracts.
- Combining mucus adhesion and penetration at the nanoscale enabled efficient local antigen delivery and strong airway immunity.
Methodological Strengths
- Rational nanomaterial design integrating mucoadhesion and mucus penetration for intranasal delivery.
- Demonstration of long-term (≥1 year) systemic and mucosal immune durability alongside virologic efficacy.
Limitations
- Preclinical study; species, dosing, and safety require phase 1 translation.
- Manufacturability and stability for large-scale distribution need evaluation.
Future Directions: Conduct first-in-human safety/immunogenicity studies, benchmark against injectable boosters, and assess transmission impact via controlled human infection or household studies.
Respiratory viral infections, such as influenza and coronavirus, are major threats to humankind. Injectable vaccines for SARS-CoV-2 protect against severe disease but fail to induce immunity in the upper airway mucosa, the virus entry site, thus not preventing infection and transmission. This highlights the urgent need for mucosal-targeted vaccination systems. While intranasal immunization holds promise, achieving local antigen delivery for mucosal immunity remains challenging. To address this, we designed an innovative nanoparticle system to deliver intranasal vaccines, using the receptor-binding domain (RBD) and multiple T-cell epitopes of SARS-CoV-2 antigens. Nonporous silica-based nanoparticles (SiNP) functionalized with a mucoadhesive cyclodextrin polymer (MaP) were selected as a delivery vehicle capable of adhering to and penetrating mucus. In a 3-dose regimen, the nanovaccine induced and sustained high systemic and neutralizing antibody levels for at least 1 year, with robust cellular responses, as well as IgA secretion in the oral and nasal cavities, providing strong protection against SARS-CoV-2 and substantially reducing viral loads in both upper and lower respiratory tracts. Our findings provide evidence that an intranasal vaccination platform combining two distinct nanoscale strategies might be crucial for inducing lasting and broad systemic and upper airway immunity, potentially controlling SARS-CoV-2 infection and transmission.